Filing Flows › Companies › P3 Health Partners › Timeline
P3 Health Partners stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions−50.2% to $4.00
P3 Health Partners (PIII) stock fell 50% over the last 252 sessions, to $4.00. On the way it reported 4 quarters, its insiders filed 1 open-market trade, and the company filed 9 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Sep 11, 2026 | 8-K | Material definitive agreement | −2.6% (−2.2% vs SPY) | −9.4% (−9.3% vs SPY) | −64.1% (−66.2% vs SPY) |
| Aug 10, 2026 | Earnings | Earnings: beat the EPS estimate by 66.8% | +10.3% (+10.3% vs SPY) | −8.0% (−8.4% vs SPY) | −25.4% (−24.5% vs SPY) |
| Aug 10, 2026 | Insider sale | Hudson Vegas Investment Manager, LLC sold $824K | +10.3% (+10.3% vs SPY) | −8.0% (−8.4% vs SPY) | −25.4% (−24.5% vs SPY) |
| Jul 6, 2026 | 8-K | Material definitive agreement | +2.3% (+2.8% vs SPY) | +1.7% (+2.0% vs SPY) | +0.9% (−1.8% vs SPY) |
| May 26, 2026 | 8-K | Delisting notice or listing-rule failure | +20.4% (+20.4% vs SPY) | −1.5% (−2.7% vs SPY) | −19.6% (−17.7% vs SPY) |
| May 15, 2026 | 8-K | Delisting notice or listing-rule failure | −20.8% (−20.7% vs SPY) | +15.6% (+14.8% vs SPY) | +0.5% (−1.0% vs SPY) |
| May 14, 2026 | Earnings | Earnings: beat the EPS estimate by 109.1% | +12.1% (+11.3% vs SPY) | +99.9% (+100.0% vs SPY) | +123.1% (+123.2% vs SPY) |
| Apr 28, 2026 | 8-K | Material definitive agreement | −3.3% (−3.3% vs SPY) | −0.2% (−1.9% vs SPY) | +173.8% (+168.0% vs SPY) |
| Mar 26, 2026 | Earnings | Earnings: missed the EPS estimate by -143.2% | −10.9% (−9.1% vs SPY) | −12.7% (−12.4% vs SPY) | −16.4% (−24.7% vs SPY) |
| Mar 25, 2026 | 8-K | Material definitive agreement | −10.9% (−9.1% vs SPY) | −12.7% (−12.4% vs SPY) | −16.4% (−24.7% vs SPY) |
| Feb 17, 2026 | 8-K | Material definitive agreement | −2.9% (−3.4% vs SPY) | −1.9% (−2.6% vs SPY) | +23.3% (+26.6% vs SPY) |
| Nov 28, 2025 | 8-K | Delisting notice or listing-rule failure | −3.6% (−4.2% vs SPY) | −6.4% (−7.1% vs SPY) | −46.1% (−47.6% vs SPY) |
| Nov 14, 2025 | 8-K | Material definitive agreement | −13.4% (−12.5% vs SPY) | −18.0% (−16.1% vs SPY) | −39.9% (−41.0% vs SPY) |
| Nov 13, 2025 | Earnings | Earnings: missed the EPS estimate by -60.2% | −8.5% (−6.8% vs SPY) | −21.9% (−18.8% vs SPY) | −38.5% (−38.2% vs SPY) |
Insiders’ record here
In the year on the chart, P3 Health Partners' insiders reported 0 open-market buys ($0) and 1 sale ($824K). Of the 1 old enough to score, 1 were followed by the stock doing what the trade implied over the next 63 sessions (beating SPY after a buy, lagging it after a sale); the median excess return after a buy was — and after a sale −63.3%.
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
| 3.01 Delisting notice or listing-rule failure | 492 | 0.0% | 46% | −0.2% | ±2.1% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → P3 Health Partners: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.